Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas-Reference-Cited by-同舟云学术

Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas

Published:2011-05-26 Issue:3 Volume:129 Page:659-670
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Felsberg Jörg,Thon Niklas,Eigenbrod Sabina,Hentschel Bettina,Sabel Michael C.,Westphal Manfred,Schackert Gabriele,Kreth Friedrich Wilhelm,Pietsch Torsten,Löffler Markus,Weller Michael,Reifenberger Guido,Tonn Jörg C.,

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference38 articles.

1. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas;Ohgaki;J Neuropathol Exp Neurol,2005

2. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;Stupp;N Engl J Med,2005

3. MGMT gene silencing and benefit from temozolomide in glioblastoma;Hegi;N Engl J Med,2005

4. MGMT promoter methylation in malignant gliomas: ready for personalized medicine?;Weller;Nat Rev Neurol,2010

5. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy;Dunn;Br J Cancer,2009

Cited by 251 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PDCD10 Is a Key Player in TMZ-Resistance and Tumor Cell Regrowth: Insights into Its Underlying Mechanism in Glioblastoma Cells;Cells;2024-08-28

2. ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma;Nature Communications;2024-06-21

3. Natural products for combating multidrug resistance in cancer;Pharmacological Research;2024-04

4. DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology;Neuro-Oncology;2024-03-22

5. ARF4-mediated retrograde trafficking as a driver of chemoresistance in glioblastoma;Neuro-Oncology;2024-03-20